Global Non-small Cell Lung Cancer Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
The Non-small Cell Lung Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Non-small Cell Lung Cancer Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Non-small Cell Lung Cancer Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Non-small Cell Lung Cancer Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Biologics
Small Molecule Targeted Therapy
Chemotherapy
Other
Market segment by Application, can be divided into
Lung Adenocarcinoma
Squamous Cell Lung Carcinoma
Large-cell Lung Carcinoma
Market segment by players, this report covers
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Non-small Cell Lung Cancer Drugs
1.2 Classification of Non-small Cell Lung Cancer Drugs by Type
1.2.1 Overview: Global Non-small Cell Lung Cancer Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Type in 2020
1.2.3 Biologics
1.2.4 Small Molecule Targeted Therapy
1.2.5 Chemotherapy
1.2.6 Other
1.3 Global Non-small Cell Lung Cancer Drugs Market by Application
1.3.1 Overview: Global Non-small Cell Lung Cancer Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Lung Adenocarcinoma
1.3.3 Squamous Cell Lung Carcinoma
1.3.4 Large-cell Lung Carcinoma
1.4 Global Non-small Cell Lung Cancer Drugs Market Size & Forecast
1.5 Global Non-small Cell Lung Cancer Drugs Market Size and Forecast by Region
1.5.1 Global Non-small Cell Lung Cancer Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Non-small Cell Lung Cancer Drugs Market Size by Region, (2016-2021)
1.5.3 North America Non-small Cell Lung Cancer Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Non-small Cell Lung Cancer Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Non-small Cell Lung Cancer Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Non-small Cell Lung Cancer Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-small Cell Lung Cancer Drugs Market Drivers
1.6.2 Non-small Cell Lung Cancer Drugs Market Restraints
1.6.3 Non-small Cell Lung Cancer Drugs Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Product and Solutions
2.1.4 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product and Solutions
2.2.4 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product and Solutions
2.3.4 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Eli Lilly and Company Recent Developments and Future Plans
2.4 F. Hoffmann-La Roche Ltd
2.4.1 F. Hoffmann-La Roche Ltd Details
2.4.2 F. Hoffmann-La Roche Ltd Major Business
2.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product and Solutions
2.4.4 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.5 Merck & Co., Inc.
2.5.1 Merck & Co., Inc. Details
2.5.2 Merck & Co., Inc. Major Business
2.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product and Solutions
2.5.4 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Merck & Co., Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Non-small Cell Lung Cancer Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-small Cell Lung Cancer Drugs Players Market Share
3.2.2 Top 10 Non-small Cell Lung Cancer Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Non-small Cell Lung Cancer Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Non-small Cell Lung Cancer Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Non-small Cell Lung Cancer Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Application (2016-2021)
5.2 Non-small Cell Lung Cancer Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2026)
6.2 North America Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2026)
6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Country
6.3.1 North America Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2026)
6.3.2 United States Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2026)
7.2 Europe Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2026)
7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Country
7.3.1 Europe Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2026)
7.3.2 Germany Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
7.3.3 France Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region
8.3.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Region (2016-2026)
8.3.2 China Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
8.3.5 India Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2026)
9.2 South America Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2026)
9.3 South America Non-small Cell Lung Cancer Drugs Market Size by Country
9.3.1 South America Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country
10.3.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Non-small Cell Lung Cancer Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Non-small Cell Lung Cancer Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Non-small Cell Lung Cancer Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Non-small Cell Lung Cancer Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Non-small Cell Lung Cancer Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Non-small Cell Lung Cancer Drugs Product and Solutions
Table 9. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Company Major Business
Table 12. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product and Solutions
Table 13. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 15. Eli Lilly and Company Major Business
Table 16. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product and Solutions
Table 17. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 19. F. Hoffmann-La Roche Ltd Major Business
Table 20. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product and Solutions
Table 21. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Merck & Co., Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Merck & Co., Inc. Major Business
Table 24. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product and Solutions
Table 25. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Global Non-small Cell Lung Cancer Drugs Revenue (USD Million) by Players (2019-2021)
Table 27. Global Non-small Cell Lung Cancer Drugs Revenue Share by Players (2019-2021)
Table 28. Breakdown of Non-small Cell Lung Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 29. Non-small Cell Lung Cancer Drugs Players Head Office, Products and Services Provided
Table 30. Non-small Cell Lung Cancer Drugs Mergers & Acquisitions in the Past Five Years
Table 31. Non-small Cell Lung Cancer Drugs New Entrants and Expansion Plans
Table 32. Global Non-small Cell Lung Cancer Drugs Revenue (USD Million) by Type (2016-2021)
Table 33. Global Non-small Cell Lung Cancer Drugs Revenue Share by Type (2016-2021)
Table 34. Global Non-small Cell Lung Cancer Drugs Revenue Forecast by Type (2021-2026)
Table 35. Global Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2021)
Table 36. Global Non-small Cell Lung Cancer Drugs Revenue Forecast by Application (2021-2026)
Table 37. North America Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 38. North America Non-small Cell Lung Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 39. North America Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 40. North America Non-small Cell Lung Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 41. North America Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 42. North America Non-small Cell Lung Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 43. Europe Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 44. Europe Non-small Cell Lung Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 45. Europe Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 46. Europe Non-small Cell Lung Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 47. Europe Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 48. Europe Non-small Cell Lung Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 49. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 50. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 51. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 52. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 53. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Region (2016-2021) & (USD Million)
Table 54. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue by Region (2021-2026) & (USD Million)
Table 55. South America Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 56. South America Non-small Cell Lung Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 57. South America Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 58. South America Non-small Cell Lung Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 59. South America Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 60. South America Non-small Cell Lung Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 61. Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 62. Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 63. Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 64. Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 65. Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 66. Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Non-small Cell Lung Cancer Drugs Picture
Figure 2. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Type in 2020
Figure 3. Biologics
Figure 4. Small Molecule Targeted Therapy
Figure 5. Chemotherapy
Figure 6. Other
Figure 7. Non-small Cell Lung Cancer Drugs Revenue Market Share by Application in 2020
Figure 8. Lung Adenocarcinoma Picture
Figure 9. Squamous Cell Lung Carcinoma Picture
Figure 10. Large-cell Lung Carcinoma Picture
Figure 11. Global Non-small Cell Lung Cancer Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Non-small Cell Lung Cancer Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Region (2016-2026)
Figure 14. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Region in 2020
Figure 15. North America Non-small Cell Lung Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Non-small Cell Lung Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Non-small Cell Lung Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Non-small Cell Lung Cancer Drugs Market Drivers
Figure 21. Non-small Cell Lung Cancer Drugs Market Restraints
Figure 22. Non-small Cell Lung Cancer Drugs Market Trends
Figure 23. AstraZeneca Recent Developments and Future Plans
Figure 24. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 25. Eli Lilly and Company Recent Developments and Future Plans
Figure 26. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 27. Merck & Co., Inc. Recent Developments and Future Plans
Figure 28. Global Non-small Cell Lung Cancer Drugs Revenue Share by Players in 2020
Figure 29. Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 30. Global Top 3 Players Non-small Cell Lung Cancer Drugs Revenue Market Share in 2020
Figure 31. Global Top 10 Players Non-small Cell Lung Cancer Drugs Revenue Market Share in 2020
Figure 32. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 33. Global Non-small Cell Lung Cancer Drugs Revenue Share by Type in 2020
Figure 34. Global Non-small Cell Lung Cancer Drugs Market Share Forecast by Type (2021-2026)
Figure 35. Global Non-small Cell Lung Cancer Drugs Revenue Share by Application in 2020
Figure 36. Global Non-small Cell Lung Cancer Drugs Market Share Forecast by Application (2021-2026)
Figure 37. North America Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 38. North America Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 39. North America Non-small Cell Lung Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 40. United States Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 44. Europe Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 45. Europe Non-small Cell Lung Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 46. Germany Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. France Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. United Kingdom Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Russia Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Italy Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 52. Asia-Pacific Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 53. Asia-Pacific Non-small Cell Lung Cancer Drugs Revenue Market Share by Region (2016-2026)
Figure 54. China Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Japan Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. South Korea Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. India Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Southeast Asia Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Australia Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South America Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 61. South America Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 62. South America Non-small Cell Lung Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 63. Brazil Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Argentina Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Middle East and Africa Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 66. Middle East and Africa Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 67. Middle East and Africa Non-small Cell Lung Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 68. Turkey Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Saudi Arabia Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. UAE Non-small Cell Lung Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Methodology
Figure 72. Research Process and Data Source
